These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17603402)

  • 41. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
    Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
    Stryjer R; Budnik D; Ebert T; Green T; Polak L; Weizman S; Spivak B
    Clin Neuropharmacol; 2014; 37(3):79-81. PubMed ID: 24824662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.
    Stein DJ; Andersen EW; Tonnoir B; Fineberg N
    Curr Med Res Opin; 2007 Apr; 23(4):701-11. PubMed ID: 17407626
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability.
    Levy DM; Arush OB; Carmi L; Wetzler AJ; Zohar J
    Compr Psychiatry; 2024 Aug; 133():152486. PubMed ID: 38703743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.
    Pessina E; Albert U; Bogetto F; Maina G
    Int Clin Psychopharmacol; 2009 Sep; 24(5):265-9. PubMed ID: 19629012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases.
    Thomsen PH
    J Child Adolesc Psychopharmacol; 1997; 7(3):157-66. PubMed ID: 9466233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder.
    Stein DJ; Montgomery SA; Kasper S; Tanghoj P
    Int Clin Psychopharmacol; 2001 Nov; 16(6):357-61. PubMed ID: 11712625
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.
    Mundo E; Bianchi L; Bellodi L
    J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Ward H; Shapira NA; Sallee FR; Gamel N; Elliott M
    J Clin Psychopharmacol; 2006 Feb; 26(1):79-83. PubMed ID: 16415712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of the selective serotonin reuptake inhibitor citalopram in a possible animal analogue of obsessive-compulsive disorder.
    Stein DJ; Mendelsohn I; Potocnik F; Van Kradenberg J; Wessels C
    Depress Anxiety; 1998; 8(1):39-42. PubMed ID: 9750979
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation.
    Grant JE; Potenza MN
    Int Clin Psychopharmacol; 2006 Jul; 21(4):203-9. PubMed ID: 16687991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
    Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
    J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impulse control disorders in patients with obsessive-compulsive disorder.
    Fontenelle LF; Mendlowicz MV; Versiani M
    Psychiatry Clin Neurosci; 2005 Feb; 59(1):30-7. PubMed ID: 15679537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.
    Storch EA; Goddard AW; Grant JE; De Nadai AS; Goodman WK; Mutch PJ; Medlock C; Odlaug B; McDougle CJ; Murphy TK
    J Clin Psychiatry; 2013 Jun; 74(6):e527-32. PubMed ID: 23842022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of eye movement desensitization and reprocessing with citalopram in treatment of obsessive-compulsive disorder.
    Nazari H; Momeni N; Jariani M; Tarrahi MJ
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):270-4. PubMed ID: 22122001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
    CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S; Mokhtari S; Shariat SV; Shariati B; Yarahmadi M; Shalbafan M
    BMC Psychiatry; 2022 Jan; 22(1):34. PubMed ID: 35022014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Tükel R; Bozkurt O; Polat A; Genç A; Atli H
    Psychiatry Clin Neurosci; 2006 Aug; 60(4):404-9. PubMed ID: 16884439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.